Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes

Luscombe, Christopher J.; French, Morris L. V.; Liu, S; Saxby, Mark F.; Jones, Peter W.; Fryer, Anthony A.; Strange, Richard C.

doi:10.1054/bjoc.2001.2097

Cited by 63 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…G 2560+9 -C 3944 was also associated with BCC risk in subjects with high and low levels of exposure to UVR. Interestingly, studies in prostate cancer patients have shown that the association of both tyrosinase and vitamin D receptor variants with risk is mediated by the extent of exposure to UVR (Luscombe et al 2001b;Bodiwala et al 2004).…”

Section: Discussionmentioning

confidence: 99%

Susceptibility to Basal Cell Carcinoma: Associations with PTCH Polymorphisms

Strange

El-Genidy

Ramachandran

et al. 2004

Annals of Human Genetics

View full text Add to dashboard Cite

SummaryLoss of function of the human patched gene (PTCH) is common and critical in basal cell carcinoma (BCC) haplotype was lower in all cases (odds ratio = 0.44, p = 0.009) and those stratified by BCC site and rate of development of further tumours. This association was not mediated by the extent of UVR exposure. We confirmed the robustness of these findings by showing these associations demonstrated similar odds ratios in two groups of randomly selected cases and controls, and using the false positive report probability (FPRP) approach described by Wacholder et al. (2004). The FPRP value (0.168) was in the noteworthy category. These data, showing for the first time that PTCH polymorphism mediates susceptibility, are compatible with reports showing that PTCH haploinsufficiency influences development of BCC precursor lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

Susceptibility to Basal Cell Carcinoma: Associations with PTCH Polymorphisms

Strange

El-Genidy

Ramachandran

et al. 2004

Annals of Human Genetics

View full text Add to dashboard Cite

show abstract

“…Studies that only used PSA level or bone scan to assess prostate cancer stage were excluded, as these are not valid or reliable methods for cancer staging (n = 2 studies; refs. 39,40). No articles were excluded based on language.…”

Section: Participants and Methodsmentioning

confidence: 99%

Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review

Chen

Smith²,

Evans³

et al. 2009

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Low levels of plasma vitamin D have been implicated as a possible risk factor for both prostate cancer incidence and advanced disease, and recent phase II trials suggest that vitamin D supplementation might delay progression of prostate cancer. Common polymorphisms in the vitamin D receptor (VDR) are associated with VDR activity and are therefore potentially useful proxies for assessing whether vitamin D is causally related to advanced prostate cancer. We genotyped five well-known VDR polymorphisms in 1,604 men with prostate cancer from the Prostate Testing for Cancer and Treatment study. Our aim was to examine the association between VDR polymorphisms and cancer stage (localized versus advanced) as well as cancer grade (Gleason score <7 versus ≥7). Moreover, we also carried out a systematic review and meta-analysis of 13 similar studies. As a result of our meta-analysis, we revealed three polymorphisms, BsmI, ApaI, and TaqI, associated with high Gleason score with an overall summary odds ratios (95% confidence intervals) of 1.12 (1.00-1.25; bb versus BB + Bb), 1.25 (1.02-1.53; aa versus AA + Aa), and 0.82 (0.69-0.98; Tt + tt versus TT), respectively. The haplotype analysis revealed that the BsmI (B)-ApaI (A)-TaqI (t) participants compared with BsmI (b)-ApaI (a)-TaqI (T) individuals were less likely to have high Gleason scores (odds ratio, 0.84; 95% confidence interval, 0.71-1.00; P unadjusted = 0.050; P adjusted = 0.014). Our finding provides some support for the hypothesis that low levels of vitamin D may increase the risk of prostate cancer progression. (Cancer Epidemiol Biomarkers Prev 2009;18(11):2874-81)

show abstract

“…Hence, they concluded that susceptibility to prostate cancer is associated with an interaction between host predisposition and sun exposure. 122 …”

Section: Search Strategy and Selection Criteriamentioning

confidence: 99%

Vitamin D and prostate cancer risk: a review of the epidemiological literature

Gupta

Lammersfeld

Trukova

et al. 2009

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Prostate cancer is the most commonly diagnosed cancer in the United States. Prostate cells contain vitamin D receptors as well as enzymes necessary for vitamin D metabolism. Vitamin D metabolites have an antiproliferative and a pro-differentiating effect on prostate cancer cell lines in vitro and in vivo. As a result, there has been an emerging interest in the potential role of vitamin D in the etiology of prostate cancer. This review summarizes all available epidemiological literature on the association between dietary vitamin D, circulating levels of vitamin D and sunlight exposure in relation to prostate cancer risk. To place these studies in context, we also provide some background information on vitamin D, such as its dietary sources, metabolism, optimal levels, hypovitaminosis and relationship with the prostate.

show abstract

Prostate cancer risk: associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes

Cited by 63 publications

References 24 publications

Susceptibility to Basal Cell Carcinoma: Associations with PTCH Polymorphisms

Susceptibility to Basal Cell Carcinoma: Associations with PTCH Polymorphisms

Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review

Vitamin D and prostate cancer risk: a review of the epidemiological literature

Contact Info

Product

Resources

About